Short-course radiotherapy-based total neoadjuvant therapy combined with tislelizumab in the treatment of locally advanced rectal cancer (Neo-STAR): Early outcomes of a prospective, randomized phase II trial
机构：[1]Department of Radiation Oncology, the Fourth Hospital of Hebei Medical University, Shijiazhuang, China河北医科大学第四医院[2]The Second Department of Surgery, the Fourth Hospital of Hebei Medical University, Shijiazhuang, China临床科室外二科河北医科大学第四医院[3]Department of Gastroenterology, the Fourth Hospital of Hebei Medical University, Shijiazhuang, China临床科室消化内科河北医科大学第四医院[4]The Fourth Hospital of Hebei Medical University, Shijiazhuang, China河北医科大学第四医院
第一作者机构：[1]Department of Radiation Oncology, the Fourth Hospital of Hebei Medical University, Shijiazhuang, China
推荐引用方式(GB/T 7714)：
Wu Fengpeng,Xiao Linlin,Zhou Chaoxi,et al.Short-course radiotherapy-based total neoadjuvant therapy combined with tislelizumab in the treatment of locally advanced rectal cancer (Neo-STAR): Early outcomes of a prospective, randomized phase II trial[J].JOURNAL OF CLINICAL ONCOLOGY.2025,43(4_SUPPL):150-150.doi:10.1200/JCO.2025.43.4_suppl.150.
APA：
Wu, Fengpeng,Xiao, Linlin,Zhou, Chaoxi,Niu, Wenbo,Fan, Haiyan...&Wang, Guiying.(2025).Short-course radiotherapy-based total neoadjuvant therapy combined with tislelizumab in the treatment of locally advanced rectal cancer (Neo-STAR): Early outcomes of a prospective, randomized phase II trial.JOURNAL OF CLINICAL ONCOLOGY,43,(4_SUPPL)
MLA：
Wu, Fengpeng,et al."Short-course radiotherapy-based total neoadjuvant therapy combined with tislelizumab in the treatment of locally advanced rectal cancer (Neo-STAR): Early outcomes of a prospective, randomized phase II trial".JOURNAL OF CLINICAL ONCOLOGY 43..4_SUPPL(2025):150-150
医学